Secukinumab in plaque psoriasis--results of two phase 3 trials.

Langley, Richard G;Elewski, Boni E;Lebwohl, Mark;Reich, Kristian;Papavassilis, Charis;et.al.
(2014) New England Journal of Medicine —

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 605.28 KB
Request a copy

Details

Authors
  • Langley, Richard G
    Author
  • Elewski, Boni E
    Author
  • Lebwohl, Mark
    Author
  • Reich, Kristian
    Author
  • Ghislain, Pierre-DominiqueUCLouvain
    Collaborator
  • Papavassilis, Charis
    Author
Show more
Abstract
Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C. (2014). Secukinumab in plaque psoriasis--results of two phase 3 trials. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1314258